|
16/10/2018 |
Maximum Residue Limits - Report: Isoflurane (porcine species): European public maximum-residue-limit assessment report (EPMAR) - CVMP
|
|
16/10/2018 |
Human medicines European public assessment report (EPAR): benralizumab, Fasenra, benralizumab, Asthma, 08/01/2018, 2, Authorised |
|
16/10/2018 |
Periodic safety update single assessment: Lomustine: List of nationally authorised medicinal products - PSUSA/00001902/201801
|
|
16/10/2018 |
Human medicines European public assessment report (EPAR): fosamprenavir, Telzir, fosamprenavir, HIV Infections, 12/07/2004, 39, Authorised |
|
16/10/2018 |
Human medicines European public assessment report (EPAR): human normal immunoglobulin, Flebogamma DIF (previously Flebogammadif), human normal immunoglobulin, Mucocutaneous Lymph Node Syndrome, Guillain-Barre Syndrome, Bone Marrow Transplantation, Purpura, Thrombocytopenic, Idiopathic, Immunologic Deficiency Syndromes, 23/07/2007, 15, Authorised |
|
16/10/2018 |
Human medicines European public assessment report (EPAR): dupilumab, Dupixent, dupilumab, Dermatitis, Atopic, 27/09/2017, 2, Authorised |
|
16/10/2018 |
Human medicines European public assessment report (EPAR): idarucizumab, Praxbind, idarucizumab, Hemorrhage, 20/11/2015, 5, Authorised |
|
16/10/2018 |
Veterinary medicines European public assessment report (EPAR): dexmedetomidine, Cepedex, dexmedetomidine, 13/12/2016, 2, Authorised |
|
16/10/2018 |
PSUSA - List of nationally authorised medicinal products (NAPs): Hydrochlorothiazide / losartan: List of nationally authorised medicinal products - PSUSA/00001655/201802
|
|
16/10/2018 |
Agenda: Agenda - PDCO agenda of the 16-19 October 2018 meeting
|
